Subtype
Gastroesophageal Junction Carcinoma
CI-CAN-00005404Explore in graph →
231 active trials9 approved drugs25 evidence items
- NCIt
- C203675
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005404Explore in graph →
Clinical trials
707 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05069766 | Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences | completed | N/A | 10 | Rigshospitalet, DenmarkOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05591053 | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | unknown | N/A | 70 | Activ SurgicalINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 14 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT02918162 | Perioperative Chemo and Pembrolizumab in Gastric Cancer | completed | Phase 2 | 49 | Gulam ManjiOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03990025 | Linked Color Imaging vs White Light Imaging for Detection of Gastric Cancer Precursors | completed | N/A | 90 | Changi General HospitalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04074343 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 1 | 20 | University of California, IrvineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06238752 | First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC(RENMIN-213) | completed | Phase 2 | 33 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03196232 | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | completed | Phase 2 | 3 | George Albert FisherOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | completed | Phase 2 | 18 | Ashwin SomasundaramOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06163365 | Inherited Cancer Early Diagnosis (ICED) Study(ICED) | unknown | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06152783 | Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study | unknown | — | 578 | Changhai HospitalOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT02287129 | Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction(MEMORI) | completed | Phase 2 | 75 | Technical University of MunichOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT03395847 | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma | completed | Early Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04999332 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer(LOTS) | unknown | Phase 2 | 58 | National Cheng-Kung University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | terminated | N/A | 32 | Erasme University HospitalOTHER | 3 | Oct 23, 2023 | clinicaltrials |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas(REGIRI) | terminated | Phase 1 / Phase 2 | 89 | UNICANCEROTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT04943406 | Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer(LIQUID) | unknown | — | 150 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02971956 | Pembrolizumab in Refractory Advanced Esophageal Cancer | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05235906 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 61 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05978882 | Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4) | not yet recruiting | N/A | 203 | National Cancer Center, KoreaOTHER_GOV | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05974059 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05954117 | Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia(CHIFMEOE) | not yet recruiting | N/A | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03427346 | Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection(BEEPER) | unknown | N/A | 407 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | Jun 28, 2023 | clinicaltrials |
| NCT05247346 | Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements(SENSITIVE) | unknown | N/A | 60 | University Medical Center GroningenOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05393986 | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | unknown | Phase 1 | 63 | Peking UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors | suspended | Phase 1 | 220 | Bellicum PharmaceuticalsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05816863 | Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma | unknown | — | 32 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT01333033 | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy | completed | Phase 2 | 257 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT04047953 | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | recruiting | N/A | 95 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05690958 | Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening(ACCEPT-survey) | unknown | — | 2,088 | Radboud University Medical CenterOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800236 | Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine(MICROGAS) | unknown | N/A | 20 | University Hospital, BordeauxOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03918499 | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 9 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2024source: clinicaltrials